{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:03:24Z","timestamp":1774573404931,"version":"3.50.1"},"reference-count":104,"publisher":"American Association for Laboratory Animal Science","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    Grapiprant belongs to the newer piprant class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is FDA approved for treatment of osteoarthritis in dogs. The compounds act as an antagonist at the prostaglandin E\n                    <jats:sub>2<\/jats:sub>\n                    EP4 receptor and is therefore also noncyclooxygenase inhibiting. This mechanism of action reduces the potential for adverse side effects associated with cyclooxygenase inhibition and makes it a promising drug for long-term use in nonhuman primates (NHPs) with chronic inflammatory conditions. In this study, we sought to establish pharmacokinetic parameters of an oral oil suspension of grapiprant in healthy, fasted male and female rhesus macaques (\n                    <jats:italic>Macaca mulatta<\/jats:italic>\n                    ) with a single oral dose of 2 mg\/kg, the current FDA-approved dose in dogs. Blood was collected at time 0 (baseline) and at 9 additional time points (0.25, 0.5, 1, 2, 4, 8, 12, 24, and 48 h) after dosing. Grapiprant plasma concentration was quantified using liquid chromatography\u2013tandem mass spectrometry. Our data show that rhesus macaques absorb grapiprant more slowly (T\n                    <jats:sub>max<\/jats:sub>\n                    = 2 h for all subjects) and at a lower level (C\n                    <jats:sub>max<\/jats:sub>\n                    = 23.8\u2009\u00b1\u200919.6 ng\/mL, AUC\n                    <jats:sub>last<\/jats:sub>\n                    = 77.5\u2009\u00b1\u200942.9 ng\u00b7h\/mL) than published values in dogs. No significant difference was noted in pharmacokinetic parameters between males and females; however, females showed more variability in pharmacokinetic parameters than did males. Significant age effects were not observed, although a positive correlation between C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>last<\/jats:sub>\n                    with age in males was noted. Our data suggest that higher doses should be explored in rhesus macaques, with a need for further investigation into the pharmacodynamics of grapiprant to establish an efficacious therapeutic dose in this species and other NHPs.\n                  <\/jats:p>","DOI":"10.30802\/aalas-jaalas-24-156","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T20:04:40Z","timestamp":1742933080000},"page":"488-494","source":"Crossref","is-referenced-by-count":0,"title":["Single-Dose Pharmacokinetics of Grapiprant in Rhesus Macaques (Macaca mulatta)"],"prefix":"10.30802","volume":"64","author":[{"given":"Lauren A","family":"Wierenga","sequence":"first","affiliation":[{"name":"Veterinary Services Unit, Wisconsin National Primate Research Center, University of Wisconsin\u2013Madison, Madison, Wisconsin;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Fitz","sequence":"additional","affiliation":[{"name":"Veterinary Services Unit, Wisconsin National Primate Research Center, University of Wisconsin\u2013Madison, Madison, Wisconsin;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Assay Services Unit, Wisconsin National Primate Research Center, University of Wisconsin\u2013Madison, Madison, Wisconsin; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian J","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Chemistry, University of Wisconsin\u2013Madison, Madison, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Capuano","sequence":"additional","affiliation":[{"name":"Veterinary Services Unit, Wisconsin National Primate Research Center, University of Wisconsin\u2013Madison, Madison, Wisconsin;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"12258","reference":[{"key":"bib1","series-title":"Animals (Basel)","first-page":"2304","article-title":"Challenges with assessing and treating pain in research primates: A focused survey and literature review","volume":"12","author":"Paterson EA","year":"2022","unstructured":"Paterson EA, Turner PV. 2022. Challenges with assessing and treating pain in research primates: A focused survey and literature review. Animals (Basel) 12:2304."},{"key":"bib2","unstructured":"Ghlichloo I, Gerriets V. [Internet]. 2023. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547742\/. Accessed May 29, 2024."},{"key":"bib3","series-title":"Pharmacol Rev","first-page":"387","article-title":"Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons DL","year":"2004","unstructured":"Simmons DL, Botting RM, Hla T. 2004. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387\u2013437."},{"key":"bib4","series-title":"J Pharm Pharm Sci","first-page":"821","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh S","year":"2013","unstructured":"Harirforoosh S, Asghar W, Jamali F. 2013. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 16:821\u2013847."},{"key":"bib5","series-title":"J Vet Intern Med","first-page":"1011","article-title":"Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs","volume":"27","author":"Monteiro-Steagall BP","year":"2013","unstructured":"Monteiro-Steagall BP, Steagall PVM, Lascelles BDX. 2013. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med 27:1011\u20131019."},{"key":"bib6","series-title":"J Vet Intern Med","first-page":"633","article-title":"The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine","volume":"19","author":"Bergh MS","year":"2005","unstructured":"Bergh MS, Budsberg SC. 2005. The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 19:633\u2013643."},{"key":"bib7","series-title":"Vet Med Sci","first-page":"3","article-title":"Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation","volume":"2","author":"Kirkby Shaw K","year":"2016","unstructured":"Kirkby Shaw K, Rausch-Derra LC, Rhodes L. 2016. Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2:3\u20139."},{"key":"bib8","series-title":"Biochim Biophys Acta","first-page":"414","article-title":"Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors","volume":"1851","author":"Kawahara K","year":"2015","unstructured":"Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. 2015. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta 1851:414\u2013421."},{"key":"bib9","series-title":"J Biol Chem","first-page":"11613","article-title":"Prostaglandin E receptors","volume":"282","author":"Sugimoto Y","year":"2007","unstructured":"Sugimoto Y, Narumiya S. 2007. Prostaglandin E receptors. J Biol Chem 282:11613\u201311617."},{"key":"bib10","series-title":"J Pharmacol Exp Ther","first-page":"1096","article-title":"Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity","volume":"319","author":"Lin C-R","year":"2006","unstructured":"Lin C-R, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ, et al. 2006. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096\u20131103."},{"key":"bib11","series-title":"J Exp Med","first-page":"325","article-title":"Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis","volume":"203","author":"Honda T","year":"2006","unstructured":"Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. 2006. Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203:325\u2013335."},{"key":"bib12","series-title":"Arterioscler Thromb Vasc Biol","first-page":"986","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti E","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. 2011. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986\u20131000."},{"key":"bib13","series-title":"Pharmacol Rev","first-page":"471","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward DF","year":"2011","unstructured":"Woodward DF, Jones RL, Narumiya S. 2011. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63:471\u2013538."},{"key":"bib14","series-title":"J Pharmacol Exp Ther","first-page":"686","article-title":"CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties","volume":"322","author":"Nakao K","year":"2007","unstructured":"Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, et al. 2007. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322:686\u2013694."},{"key":"bib15","series-title":"Pharmacol Ther","first-page":"485","article-title":"E-type prostanoid receptor 4 (EP4) in disease and therapy","volume":"138","author":"Konya V","year":"2013","unstructured":"Konya V, Marsche G, Schuligoi R, Heinemann A. 2013. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 138:485\u2013502."},{"key":"bib16","series-title":"Galliprant [package insert].","year":"2018","unstructured":"Elanco. 2018. Galliprant [package insert]. Greenfield (IN): Elanco US. Available at: https:\/\/assets.elanco.com\/0cec44ed-3eaa-0009-2029-666567e7e4de\/796b62ac-b115-45ec-839c-66bda0451bc4\/Galliprant%20Inflammation%20One%20Page%20Detailer.pdf. Accessed April 17, 2024."},{"key":"bib17","series-title":"Vet Pathol","first-page":"399","article-title":"Age-associated pathology in rhesus macaques (Macaca mulatta)","volume":"53","author":"Simmons HA","year":"2016","unstructured":"Simmons HA. 2016. Age-associated pathology in rhesus macaques (Macaca mulatta). Vet Pathol 53:399\u2013416."},{"key":"bib18","series-title":"Bone","first-page":"17","article-title":"Skeletal effects of aging in male rhesus monkeys","volume":"24","author":"Colman RJ","year":"1999","unstructured":"Colman RJ, Lane MA, Binkley N, Wegner FH, Kemnitz JW. 1999. Skeletal effects of aging in male rhesus monkeys. Bone 24:17\u201323."},{"key":"bib19","series-title":"J Clin Endocrinol Metab","first-page":"4144","article-title":"Skeletal effects of aging and menopausal status in female rhesus macaques","volume":"84","author":"Colman RJ","year":"1999","unstructured":"Colman RJ, Kemnitz JW, Lane MA, Abbott DH, Binkley N. 1999. Skeletal effects of aging and menopausal status in female rhesus macaques. J Clin Endocrinol Metab 84:4144\u20134148."},{"key":"bib20","series-title":"N Z Vet J","first-page":"19","article-title":"Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs","volume":"65","author":"\u0141ebkowska-Wieruszewska B","year":"2017","unstructured":"\u0141ebkowska-Wieruszewska B, Barsotti G, Lisowski A, Gazzano A, Owen H, Giorgi M. 2017. Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. N Z Vet J 65:19\u201323."},{"key":"bib21","series-title":"J Vet Pharmacol Ther","first-page":"285","article-title":"Pharmacology of grapiprant, a novel EP4 antagonist: Receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs","volume":"40","author":"Nagahisa A","year":"2017","unstructured":"Nagahisa A, Okumura T. 2017. Pharmacology of grapiprant, a novel EP4 antagonist: Receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Pharmacol Ther 40:285\u2013292."},{"key":"bib22","series-title":"J Vet Pharmacol Ther","first-page":"679","article-title":"Grapiprant: A snapshot of the current knowledge","volume":"44","author":"Sartini I","year":"2021","unstructured":"Sartini I, Giorgi M. 2021. Grapiprant: A snapshot of the current knowledge. J Vet Pharmacol Ther 44:679\u2013688."},{"key":"bib23","series-title":"Guide for the care and use of laboratory animals","year":"2011","unstructured":"Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press."},{"key":"bib24","first-page":"3129","year":"2013","unstructured":"Animal Welfare Regulations. 2013. 9 CFR \u00a7 3129."},{"key":"bib25","first-page":"2131","year":"2013","unstructured":"Animal Welfare Act as Amended. 2013. 7 USC \u00a72131-2159."},{"key":"bib26","article-title":"Public health service policy on humane care and use of laboratory animals","year":"2015","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health. 2015. Public health service policy on humane care and use of laboratory animals. Available at: https:\/\/olaw.nih.gov\/sites\/default\/files\/PHSPolicyLabAnimals.pdf. Accessed June 14, 2024."},{"key":"bib27","series-title":"J Am Assoc Lab Anim Sci","first-page":"88","article-title":"Validation of a body condition scoring system in rhesus macaques (Macaca mulatta): Assessment of body composition by using dual-energy x-ray absorptiometry","volume":"51","author":"Summers L","year":"2012","unstructured":"Summers L, Clingerman KJ, Yang X. 2012. Validation of a body condition scoring system in rhesus macaques (Macaca mulatta): Assessment of body composition by using dual-energy x-ray absorptiometry. J Am Assoc Lab Anim Sci 51:88\u201393."},{"key":"bib28","series-title":"J Am Assoc Lab Anim Sci","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner PV","year":"2011","unstructured":"Turner PV, Brabb T, Pekow C, Vasbinder MA. 2011. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50:600\u2013613."},{"key":"bib29","series-title":"Drug Test Anal","first-page":"1237","article-title":"Detection and pharmacokinetics of grapiprant following oral administration to exercised thoroughbred horses","volume":"10","author":"Knych HK","year":"2018","unstructured":"Knych HK, Seminoff K, McKemie DS. 2018. Detection and pharmacokinetics of grapiprant following oral administration to exercised thoroughbred horses. Drug Test Anal 10:1237\u20131243."},{"key":"bib30","year":"2019","unstructured":"Certara. 2019. [Cited 20 October 2024]. Available at: https:\/\/onlinehelp.certara.com\/phoenix\/8.2\/index.html#t=topics%2Fncaparamformulas.htm%23XREF_29718_a_For."},{"key":"bib31","series-title":"R: A language and environment for statistical computing.","year":"2022","unstructured":"R Core Team. 2022. R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. Available at: https:\/\/www.R-project.org."},{"key":"bib32","series-title":"Ann Stat","first-page":"1165","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini Y","year":"2001","unstructured":"Benjamini Y, Yekutieli D. 2001. The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165\u20131188."},{"key":"bib33","series-title":"Mol Pharm","first-page":"1634","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain P","year":"2017","unstructured":"Daublain P, Feng K-I, Altman MD, Martin I, Mukherjee S, Nofsinger R, Northrup AB, et al. 2017. Analyzing the potential root causes of variability of pharmacokinetics in preclinical species. Mol Pharm 14:1634\u20131645."},{"key":"bib34","series-title":"J Vet Pharmacol Ther","first-page":"566","article-title":"Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs","volume":"39","author":"Rausch-Derra LC","year":"2016","unstructured":"Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. 2016. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Ther 39:566\u2013571."},{"key":"bib35","series-title":"Vet Anaesth Analg","first-page":"705","article-title":"Determination of grapiprant plasma and urine concentrations in horses","volume":"47","author":"Cox S","year":"2020","unstructured":"Cox S, Sommardahl C, Fortner C, Davis R, Bergman J, Doherty T. 2020. Determination of grapiprant plasma and urine concentrations in horses. Vet Anaesth Analg 47:705\u2013709."},{"key":"bib36","series-title":"J Vet Pharmacol Ther","first-page":"269","article-title":"Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica)","volume":"46","author":"Kleine S","year":"2023","unstructured":"Kleine S, Hampton CE, Smith C, Bussieres G, Mulon P-Y, Seddighi R, Cox S, et al. 2023. Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica). J Vet Pharmacol Ther 46:269\u2013275."},{"key":"bib37","series-title":"Toxicol Pathol","first-page":"172","article-title":"Sex differences in human and animal toxicology: Toxicokinetics","volume":"45","author":"Gochfeld M","year":"2017","unstructured":"Gochfeld M. 2017. Sex differences in human and animal toxicology: Toxicokinetics. Toxicol Pathol 45:172\u2013189."},{"key":"bib38","series-title":"Biol Sex Differ","first-page":"32","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker I","year":"2020","unstructured":"Zucker I, Prendergast BJ. 2020. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ 11:32."},{"key":"bib39","series-title":"J Pharmacol Pharmacother","first-page":"303","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan J","year":"2013","unstructured":"Charan J, Kantharia ND. 2013. How to calculate sample size in animal studies? J Pharmacol Pharmacother 4:303\u2013306."},{"key":"bib40","series-title":"Br J Clin Pharmacol","first-page":"6","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications: Age-related changes in pharmacokinetics and pharmacodynamics","volume":"57","author":"Mangoni AA","year":"2004","unstructured":"Mangoni AA, Jackson SHD. 2004. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications: Age-related changes in pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 57:6\u201314."},{"key":"bib41","series-title":"Br J Clin Pharmacol","first-page":"395","article-title":"Paediatric pharmacokinetics: Key considerations: Paediatric pharmacokinetics","volume":"79","author":"Batchelor HK","year":"2015","unstructured":"Batchelor HK, Marriott JF. 2015. Paediatric pharmacokinetics: Key considerations: Paediatric pharmacokinetics. Br J Clin Pharmacol 79:395\u2013404."},{"key":"bib42","series-title":"Pediatric drug development.","first-page":"222","article-title":"Absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic assessments in juvenile animals","author":"Zwart LL d","year":"2013","unstructured":"Zwart LL d, Monbaliu JG, Annaert PP. 2013. Absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic assessments in juvenile animals, p 222\u2013245. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development. Chichester (UK): John Wiley & Sons."},{"key":"bib43","series-title":"Mediators Inflamm","first-page":"6136105","article-title":"Organ-protective effects and the underlying mechanism of dexmedetomidine","volume":"2020","author":"Bao N","year":"2020","unstructured":"Bao N, Tang B. 2020. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm 2020:6136105."},{"key":"bib44","series-title":"Animals (Basel)","first-page":"1021","article-title":"Dexmedetomidine has differential effects on the contractility of equine jejunal smooth muscle layers in vitro","volume":"13","author":"Verhaar N","year":"2023","unstructured":"Verhaar N, Hoppe S, Grages AM, Hansen K, Neudeck S, K\u00e4stner S, Mazzuoli-Weber G, et al. 2023. Dexmedetomidine has differential effects on the contractility of equine jejunal smooth muscle layers in vitro. Animals (Basel) 13:1021."},{"key":"bib45","series-title":"Anesth Analg","first-page":"1160","article-title":"The effect of dexmedetomidine on nutrient organ blood flow","volume":"83","author":"Lawrence CJ","year":"1996","unstructured":"Lawrence CJ, Prinzen FW, de Lange S. 1996. The effect of dexmedetomidine on nutrient organ blood flow. Anesth Analg 83:1160\u20131165."},{"key":"bib46","series-title":"Anesthesiology","first-page":"355","article-title":"Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats","volume":"125","author":"Yeh Y-C","year":"2016","unstructured":"Yeh Y-C, Wu C-Y, Cheng Y-J, Liu C-M, Hsiao J-K, Chan W-S, Wu Z-G, et al. 2016. Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats. Anesthesiology 125:355\u2013367."},{"key":"bib47","series-title":"Contemp Top Lab Anim Sci","first-page":"60","article-title":"Comparison of cardiovascular parameters and\/or serum chemistry and hematology profiles in conscious and anesthetized rhesus monkeys (Macaca mulatta)","volume":"38","author":"Hom GJ","year":"1999","unstructured":"Hom GJ, Bach TJ, Carroll D, Forrest MJ, Mariano MA, Trainor CE, Wang P-R, et al. 1999. Comparison of cardiovascular parameters and\/or serum chemistry and hematology profiles in conscious and anesthetized rhesus monkeys (Macaca mulatta). Contemp Top Lab Anim Sci 38:60\u201364."},{"key":"bib48","series-title":"Gut","first-page":"A39.3","article-title":"OC-091 Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome","volume":"61","author":"Garsed K","year":"2012","unstructured":"Garsed K, Hastings M, Marciani L, Lam C, Singh G, Lingaya M, Whorwell P, et al. 2012. OC-091 Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome. Gut 61:A39.3\u2013A40."},{"key":"bib49","series-title":"J Equine Vet Sci","first-page":"103427","article-title":"Does intravenous ondansetron affect the intestinal motility pattern in healthy donkeys (Equus asinus)?","volume":"101","author":"Farag AMM","year":"2021","unstructured":"Farag AMM, Ibrahim HMM. 2021. Does intravenous ondansetron affect the intestinal motility pattern in healthy donkeys (Equus asinus)? J Equine Vet Sci 101:103427."},{"key":"bib50","series-title":"Aliment Pharmacol Ther","first-page":"119","article-title":"Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers?","volume":"16","author":"Netzer P","year":"2002","unstructured":"Netzer P, Gaia C, Lourens ST, Reber P, Wildi S, Noelpp U, Ritter EP, et al. 2002. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 16:119\u2013127."},{"key":"bib51","series-title":"J Vet Pharmacol Ther","first-page":"467","article-title":"Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses","volume":"45","author":"Hoffmann SL","year":"2022","unstructured":"Hoffmann SL, Seminoff K, McKemie DS, Kass PH, Knych HK. 2022. Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses. J Vet Pharmacol Ther 45:467\u2013472."},{"key":"bib52","series-title":"Am J Vet Res","first-page":"853","article-title":"Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs","volume":"76","author":"Rausch-Derra LC","year":"2015","unstructured":"Rausch-Derra LC, Huebner M, Rhodes L. 2015. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Am J Vet Res 76:853\u2013859."},{"key":"bib1","series-title":"Animals (Basel)","first-page":"2304","article-title":"Challenges with assessing and treating pain in research primates: A focused survey and literature review","volume":"12","author":"Paterson EA","year":"2022","unstructured":"Paterson EA, Turner PV. 2022. Challenges with assessing and treating pain in research primates: A focused survey and literature review. Animals (Basel) 12:2304."},{"key":"bib2","unstructured":"Ghlichloo I, Gerriets V. [Internet]. 2023. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547742\/. Accessed May 29, 2024."},{"key":"bib3","series-title":"Pharmacol Rev","first-page":"387","article-title":"Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons DL","year":"2004","unstructured":"Simmons DL, Botting RM, Hla T. 2004. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387\u2013437."},{"key":"bib4","series-title":"J Pharm Pharm Sci","first-page":"821","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh S","year":"2013","unstructured":"Harirforoosh S, Asghar W, Jamali F. 2013. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 16:821\u2013847."},{"key":"bib5","series-title":"J Vet Intern Med","first-page":"1011","article-title":"Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs","volume":"27","author":"Monteiro-Steagall BP","year":"2013","unstructured":"Monteiro-Steagall BP, Steagall PVM, Lascelles BDX. 2013. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med 27:1011\u20131019."},{"key":"bib6","series-title":"J Vet Intern Med","first-page":"633","article-title":"The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine","volume":"19","author":"Bergh MS","year":"2005","unstructured":"Bergh MS, Budsberg SC. 2005. The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 19:633\u2013643."},{"key":"bib7","series-title":"Vet Med Sci","first-page":"3","article-title":"Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation","volume":"2","author":"Kirkby Shaw K","year":"2016","unstructured":"Kirkby Shaw K, Rausch-Derra LC, Rhodes L. 2016. Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2:3\u20139."},{"key":"bib8","series-title":"Biochim Biophys Acta","first-page":"414","article-title":"Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors","volume":"1851","author":"Kawahara K","year":"2015","unstructured":"Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. 2015. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta 1851:414\u2013421."},{"key":"bib9","series-title":"J Biol Chem","first-page":"11613","article-title":"Prostaglandin E receptors","volume":"282","author":"Sugimoto Y","year":"2007","unstructured":"Sugimoto Y, Narumiya S. 2007. Prostaglandin E receptors. J Biol Chem 282:11613\u201311617."},{"key":"bib10","series-title":"J Pharmacol Exp Ther","first-page":"1096","article-title":"Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity","volume":"319","author":"Lin C-R","year":"2006","unstructured":"Lin C-R, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ, et al. 2006. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096\u20131103."},{"key":"bib11","series-title":"J Exp Med","first-page":"325","article-title":"Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis","volume":"203","author":"Honda T","year":"2006","unstructured":"Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. 2006. Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203:325\u2013335."},{"key":"bib12","series-title":"Arterioscler Thromb Vasc Biol","first-page":"986","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti E","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. 2011. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986\u20131000."},{"key":"bib13","series-title":"Pharmacol Rev","first-page":"471","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward DF","year":"2011","unstructured":"Woodward DF, Jones RL, Narumiya S. 2011. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63:471\u2013538."},{"key":"bib14","series-title":"J Pharmacol Exp Ther","first-page":"686","article-title":"CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties","volume":"322","author":"Nakao K","year":"2007","unstructured":"Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, et al. 2007. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322:686\u2013694."},{"key":"bib15","series-title":"Pharmacol Ther","first-page":"485","article-title":"E-type prostanoid receptor 4 (EP4) in disease and therapy","volume":"138","author":"Konya V","year":"2013","unstructured":"Konya V, Marsche G, Schuligoi R, Heinemann A. 2013. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 138:485\u2013502."},{"key":"bib16","series-title":"Galliprant [package insert].","year":"2018","unstructured":"Elanco. 2018. Galliprant [package insert]. Greenfield (IN): Elanco US. Available at: https:\/\/assets.elanco.com\/0cec44ed-3eaa-0009-2029-666567e7e4de\/796b62ac-b115-45ec-839c-66bda0451bc4\/Galliprant%20Inflammation%20One%20Page%20Detailer.pdf. Accessed April 17, 2024."},{"key":"bib17","series-title":"Vet Pathol","first-page":"399","article-title":"Age-associated pathology in rhesus macaques (Macaca mulatta)","volume":"53","author":"Simmons HA","year":"2016","unstructured":"Simmons HA. 2016. Age-associated pathology in rhesus macaques (Macaca mulatta). Vet Pathol 53:399\u2013416."},{"key":"bib18","series-title":"Bone","first-page":"17","article-title":"Skeletal effects of aging in male rhesus monkeys","volume":"24","author":"Colman RJ","year":"1999","unstructured":"Colman RJ, Lane MA, Binkley N, Wegner FH, Kemnitz JW. 1999. Skeletal effects of aging in male rhesus monkeys. Bone 24:17\u201323."},{"key":"bib19","series-title":"J Clin Endocrinol Metab","first-page":"4144","article-title":"Skeletal effects of aging and menopausal status in female rhesus macaques","volume":"84","author":"Colman RJ","year":"1999","unstructured":"Colman RJ, Kemnitz JW, Lane MA, Abbott DH, Binkley N. 1999. Skeletal effects of aging and menopausal status in female rhesus macaques. J Clin Endocrinol Metab 84:4144\u20134148."},{"key":"bib20","series-title":"N Z Vet J","first-page":"19","article-title":"Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs","volume":"65","author":"\u0141ebkowska-Wieruszewska B","year":"2017","unstructured":"\u0141ebkowska-Wieruszewska B, Barsotti G, Lisowski A, Gazzano A, Owen H, Giorgi M. 2017. Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. N Z Vet J 65:19\u201323."},{"key":"bib21","series-title":"J Vet Pharmacol Ther","first-page":"285","article-title":"Pharmacology of grapiprant, a novel EP4 antagonist: Receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs","volume":"40","author":"Nagahisa A","year":"2017","unstructured":"Nagahisa A, Okumura T. 2017. Pharmacology of grapiprant, a novel EP4 antagonist: Receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Pharmacol Ther 40:285\u2013292."},{"key":"bib22","series-title":"J Vet Pharmacol Ther","first-page":"679","article-title":"Grapiprant: A snapshot of the current knowledge","volume":"44","author":"Sartini I","year":"2021","unstructured":"Sartini I, Giorgi M. 2021. Grapiprant: A snapshot of the current knowledge. J Vet Pharmacol Ther 44:679\u2013688."},{"key":"bib23","series-title":"Guide for the care and use of laboratory animals","year":"2011","unstructured":"Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press."},{"key":"bib24","first-page":"3129","year":"2013","unstructured":"Animal Welfare Regulations. 2013. 9 CFR \u00a7 3129."},{"key":"bib25","first-page":"2131","year":"2013","unstructured":"Animal Welfare Act as Amended. 2013. 7 USC \u00a72131-2159."},{"key":"bib26","article-title":"Public health service policy on humane care and use of laboratory animals","year":"2015","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health. 2015. Public health service policy on humane care and use of laboratory animals. Available at: https:\/\/olaw.nih.gov\/sites\/default\/files\/PHSPolicyLabAnimals.pdf. Accessed June 14, 2024."},{"key":"bib27","series-title":"J Am Assoc Lab Anim Sci","first-page":"88","article-title":"Validation of a body condition scoring system in rhesus macaques (Macaca mulatta): Assessment of body composition by using dual-energy x-ray absorptiometry","volume":"51","author":"Summers L","year":"2012","unstructured":"Summers L, Clingerman KJ, Yang X. 2012. Validation of a body condition scoring system in rhesus macaques (Macaca mulatta): Assessment of body composition by using dual-energy x-ray absorptiometry. J Am Assoc Lab Anim Sci 51:88\u201393."},{"key":"bib28","series-title":"J Am Assoc Lab Anim Sci","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner PV","year":"2011","unstructured":"Turner PV, Brabb T, Pekow C, Vasbinder MA. 2011. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50:600\u2013613."},{"key":"bib29","series-title":"Drug Test Anal","first-page":"1237","article-title":"Detection and pharmacokinetics of grapiprant following oral administration to exercised thoroughbred horses","volume":"10","author":"Knych HK","year":"2018","unstructured":"Knych HK, Seminoff K, McKemie DS. 2018. Detection and pharmacokinetics of grapiprant following oral administration to exercised thoroughbred horses. Drug Test Anal 10:1237\u20131243."},{"key":"bib30","year":"2019","unstructured":"Certara. 2019. [Cited 20 October 2024]. Available at: https:\/\/onlinehelp.certara.com\/phoenix\/8.2\/index.html#t=topics%2Fncaparamformulas.htm%23XREF_29718_a_For."},{"key":"bib31","series-title":"R: A language and environment for statistical computing.","year":"2022","unstructured":"R Core Team. 2022. R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. Available at: https:\/\/www.R-project.org."},{"key":"bib32","series-title":"Ann Stat","first-page":"1165","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini Y","year":"2001","unstructured":"Benjamini Y, Yekutieli D. 2001. The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165\u20131188."},{"key":"bib33","series-title":"Mol Pharm","first-page":"1634","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain P","year":"2017","unstructured":"Daublain P, Feng K-I, Altman MD, Martin I, Mukherjee S, Nofsinger R, Northrup AB, et al. 2017. Analyzing the potential root causes of variability of pharmacokinetics in preclinical species. Mol Pharm 14:1634\u20131645."},{"key":"bib34","series-title":"J Vet Pharmacol Ther","first-page":"566","article-title":"Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs","volume":"39","author":"Rausch-Derra LC","year":"2016","unstructured":"Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. 2016. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Ther 39:566\u2013571."},{"key":"bib35","series-title":"Vet Anaesth Analg","first-page":"705","article-title":"Determination of grapiprant plasma and urine concentrations in horses","volume":"47","author":"Cox S","year":"2020","unstructured":"Cox S, Sommardahl C, Fortner C, Davis R, Bergman J, Doherty T. 2020. Determination of grapiprant plasma and urine concentrations in horses. Vet Anaesth Analg 47:705\u2013709."},{"key":"bib36","series-title":"J Vet Pharmacol Ther","first-page":"269","article-title":"Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica)","volume":"46","author":"Kleine S","year":"2023","unstructured":"Kleine S, Hampton CE, Smith C, Bussieres G, Mulon P-Y, Seddighi R, Cox S, et al. 2023. Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica). J Vet Pharmacol Ther 46:269\u2013275."},{"key":"bib37","series-title":"Toxicol Pathol","first-page":"172","article-title":"Sex differences in human and animal toxicology: Toxicokinetics","volume":"45","author":"Gochfeld M","year":"2017","unstructured":"Gochfeld M. 2017. Sex differences in human and animal toxicology: Toxicokinetics. Toxicol Pathol 45:172\u2013189."},{"key":"bib38","series-title":"Biol Sex Differ","first-page":"32","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker I","year":"2020","unstructured":"Zucker I, Prendergast BJ. 2020. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ 11:32."},{"key":"bib39","series-title":"J Pharmacol Pharmacother","first-page":"303","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan J","year":"2013","unstructured":"Charan J, Kantharia ND. 2013. How to calculate sample size in animal studies? J Pharmacol Pharmacother 4:303\u2013306."},{"key":"bib40","series-title":"Br J Clin Pharmacol","first-page":"6","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications: Age-related changes in pharmacokinetics and pharmacodynamics","volume":"57","author":"Mangoni AA","year":"2004","unstructured":"Mangoni AA, Jackson SHD. 2004. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications: Age-related changes in pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 57:6\u201314."},{"key":"bib41","series-title":"Br J Clin Pharmacol","first-page":"395","article-title":"Paediatric pharmacokinetics: Key considerations: Paediatric pharmacokinetics","volume":"79","author":"Batchelor HK","year":"2015","unstructured":"Batchelor HK, Marriott JF. 2015. Paediatric pharmacokinetics: Key considerations: Paediatric pharmacokinetics. Br J Clin Pharmacol 79:395\u2013404."},{"key":"bib42","series-title":"Pediatric drug development.","first-page":"222","article-title":"Absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic assessments in juvenile animals","author":"Zwart LL d","year":"2013","unstructured":"Zwart LL d, Monbaliu JG, Annaert PP. 2013. Absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic assessments in juvenile animals, p 222\u2013245. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development. Chichester (UK): John Wiley & Sons."},{"key":"bib43","series-title":"Mediators Inflamm","first-page":"6136105","article-title":"Organ-protective effects and the underlying mechanism of dexmedetomidine","volume":"2020","author":"Bao N","year":"2020","unstructured":"Bao N, Tang B. 2020. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm 2020:6136105."},{"key":"bib44","series-title":"Animals (Basel)","first-page":"1021","article-title":"Dexmedetomidine has differential effects on the contractility of equine jejunal smooth muscle layers in vitro","volume":"13","author":"Verhaar N","year":"2023","unstructured":"Verhaar N, Hoppe S, Grages AM, Hansen K, Neudeck S, K\u00e4stner S, Mazzuoli-Weber G, et al. 2023. Dexmedetomidine has differential effects on the contractility of equine jejunal smooth muscle layers in vitro. Animals (Basel) 13:1021."},{"key":"bib45","series-title":"Anesth Analg","first-page":"1160","article-title":"The effect of dexmedetomidine on nutrient organ blood flow","volume":"83","author":"Lawrence CJ","year":"1996","unstructured":"Lawrence CJ, Prinzen FW, de Lange S. 1996. The effect of dexmedetomidine on nutrient organ blood flow. Anesth Analg 83:1160\u20131165."},{"key":"bib46","series-title":"Anesthesiology","first-page":"355","article-title":"Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats","volume":"125","author":"Yeh Y-C","year":"2016","unstructured":"Yeh Y-C, Wu C-Y, Cheng Y-J, Liu C-M, Hsiao J-K, Chan W-S, Wu Z-G, et al. 2016. Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats. Anesthesiology 125:355\u2013367."},{"key":"bib47","series-title":"Contemp Top Lab Anim Sci","first-page":"60","article-title":"Comparison of cardiovascular parameters and\/or serum chemistry and hematology profiles in conscious and anesthetized rhesus monkeys (Macaca mulatta)","volume":"38","author":"Hom GJ","year":"1999","unstructured":"Hom GJ, Bach TJ, Carroll D, Forrest MJ, Mariano MA, Trainor CE, Wang P-R, et al. 1999. Comparison of cardiovascular parameters and\/or serum chemistry and hematology profiles in conscious and anesthetized rhesus monkeys (Macaca mulatta). Contemp Top Lab Anim Sci 38:60\u201364."},{"key":"bib48","series-title":"Gut","first-page":"A39.3","article-title":"OC-091 Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome","volume":"61","author":"Garsed K","year":"2012","unstructured":"Garsed K, Hastings M, Marciani L, Lam C, Singh G, Lingaya M, Whorwell P, et al. 2012. OC-091 Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome. Gut 61:A39.3\u2013A40."},{"key":"bib49","series-title":"J Equine Vet Sci","first-page":"103427","article-title":"Does intravenous ondansetron affect the intestinal motility pattern in healthy donkeys (Equus asinus)?","volume":"101","author":"Farag AMM","year":"2021","unstructured":"Farag AMM, Ibrahim HMM. 2021. Does intravenous ondansetron affect the intestinal motility pattern in healthy donkeys (Equus asinus)? J Equine Vet Sci 101:103427."},{"key":"bib50","series-title":"Aliment Pharmacol Ther","first-page":"119","article-title":"Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers?","volume":"16","author":"Netzer P","year":"2002","unstructured":"Netzer P, Gaia C, Lourens ST, Reber P, Wildi S, Noelpp U, Ritter EP, et al. 2002. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 16:119\u2013127."},{"key":"bib51","series-title":"J Vet Pharmacol Ther","first-page":"467","article-title":"Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses","volume":"45","author":"Hoffmann SL","year":"2022","unstructured":"Hoffmann SL, Seminoff K, McKemie DS, Kass PH, Knych HK. 2022. Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses. J Vet Pharmacol Ther 45:467\u2013472."},{"key":"bib52","series-title":"Am J Vet Res","first-page":"853","article-title":"Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs","volume":"76","author":"Rausch-Derra LC","year":"2015","unstructured":"Rausch-Derra LC, Huebner M, Rhodes L. 2015. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Am J Vet Res 76:853\u2013859."}],"container-title":["Journal of the American Association for Laboratory Animal Science"],"original-title":[],"link":[{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/64\/3\/article-p488.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/64\/3\/article-p488.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/64\/3\/article-p488.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:30:34Z","timestamp":1774571434000},"score":1,"resource":{"primary":{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/64\/3\/article-p488.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":104,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.30802\/aalas-jaalas-24-156","relation":{},"ISSN":["1559-6109"],"issn-type":[{"value":"1559-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}